Trial · NCT01394211
Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer
NCT01394211, Phase 2, Terminated, University of Arizona; results first posted 2018-07-26
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer. Trials, record NCT01394211. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01394211
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer
- NCT number
- NCT01394211
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 2 participants, actual
- Lead sponsor
- University of Arizona
- Conditions
Estrogen Receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Male Breast Cancer, Recurrent Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
- Interventions
- anastrozole, pazopanib hydrochloride, therapeutic conventional surgery
- First posted
- 2011-07-14
- Last updated
- 2018-07-26
- Results first posted
- 2018-07-26
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Rate of pCR at Primary Site (T0) and Nodal Sites (T0N0) | Six months from the initiation of neoadjuvant therapy | Defined as no evidence of microscopic invasive tumor present. Determined by pathology. Estimated with an exact 95% confidence interval. |
| Secondary | Proportion of Patients Achieving Sustained Decrease in Ki-67 | 12 weeks from the initiation of neoadjuvant therapy | |
| Secondary | Proportion of Patients Achieving Down-staging to a Pathologic Stage 0 or 1 | Six months from the initiation of neoadjuvant therapy |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Rate of pCR at Primary Site (T0) and Nodal Sites (T0N0) | Six months from the initiation of neoadjuvant therapy | Participants withdrew from participation | ||
| SECONDARY | Proportion of Patients Achieving Sustained Decrease in Ki-67 | 12 weeks from the initiation of neoadjuvant therapy | Participants withdrew from participation | ||
| SECONDARY | Proportion of Patients Achieving Down-staging to a Pathologic Stage 0 or 1 | Six months from the initiation of neoadjuvant therapy | Participants withdrew from participation |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Neoadjuvant Enzyme Inhibitor Therapy | 2 | |
| Overall Study | COMPLETED | Neoadjuvant Enzyme Inhibitor Therapy | 0 | |
| Overall Study | NOT COMPLETED | Neoadjuvant Enzyme Inhibitor Therapy | 2 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Neoadjuvant Enzyme Inhibitor Therapy | ||
| Total, other adverse events | Neoadjuvant Enzyme Inhibitor Therapy | 0 | 2 |
| Total, serious adverse events | Neoadjuvant Enzyme Inhibitor Therapy | 0 | 2 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| P30CA023074 | University of Arizona Cancer Center - Cancer Center Support Grant | THEODORESCU, DAN | UNIVERSITY OF ARIZONA | NATIONAL CANCER INSTITUTE | 1985 to 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01394211
GET https://conductscience.org/api/trials/v1/NCT01394211/registered